BioSpace

Last week, BioMarin Pharmaceutical Inc. revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May. https://hubs.li/Q02N55Mr0 #pharma #biospace

In Texas, the Plano City Council approved a development agreement that supports a planned project that would bring over 3 million square feet of life sciences space to the area. https://hubs.li/Q02N54lv0 #pharma #biospace

Merck continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies of the anti-PD-1 therapy in non-small cell lung cancer and cutaneous squamous cell carcinoma. https://hubs.li/Q02N2PkT0 #pharma #biospace

Rep. James Comer (R-Ky.), chair of the House Committee on Oversight and Accountability, wants the CEOs of CVS Caremark, Express Scripts and Optum Rx—three major pharmacy benefit managers—to correct statements they made during a hearing last month. https://hubs.li/Q02N1Zkx0 #pharma #biospace

In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act. https://hubs.li/Q02N25Vl0 #pharma #biospace

Don't miss out on your chance to vote in BioSpace's Best Places to Work in Life Sciences, 2025! Voting closes August 31st. https://hubs.li/Q02N1-5z0 #bestplacestowork #pharma #biotech #biopharma #lifesciences #biospace

In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori Ellis (Katz) and guests Otis Johnson, PhD, MPA of Trial Equity, Pamela Tenaerts, MD, MBA of Medable, Inc, Christopher Escobedo Hart of Foley Hoag LLP, Patrick Floody of Regeneron, and Ken Getz of Tufts Center for the Study of Drug Development discuss framing strategies designed to protect DEI initiatives from legal challenges. https://hubs.li/Q02N1q6Q0 #pharma #podcast #biospace

Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease. https://hubs.li/Q02N0XMs0 #pharma #biospace

Neurocrine Biosciences' potential competitor to Bristol Myers Squibb's KarXT improved symptoms of schizophrenia in a Phase II trial, but only at the low dose tested. #pharma #biospace https://hubs.li/Q02MWcv60

Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition. #ftc #congress #pharmanews #biospace https://hubs.li/Q02MVQ0f0